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The ability to overexpress full-length huntingtin or large fragments represents an important challenge to
mimic Huntington’s pathology and reproduce all stages of the disease in a time frame compatible with rodent
life span. In the present study, tetracycline-regulated lentiviral vectors leading to high expression levels were
used to accelerate the pathological process. Rats were simultaneously injected with vectors coding for the
transactivator and wild type (WT) or mutated huntingtin (TRE-853-19Q/82Q) in the left and right striatum,
respectively, and analyzed in the ‘on’ and ‘off’ conditions. Overexpression of TRE-853-19Q protein or residual
expression of TRE-853-82Q in ‘off’ condition did not cause any signiﬁcant neuronal pathology.
Overexpressed TRE-853-82Q protein led to proteolytic release of N-terminal htt fragments, nuclear
aggregation, and a striatal dysfunction as revealed by decrease of DARPP-32 staining but absence of
NeuN down-regulation. The differential effect on the DARPP-32/NeuN neuronal staining was observed as
early as 1 month after injection and maintained at 3 months. In contrast, expression of a shorter htt form
(htt171-82Q) did not require processing prior formation of nuclear aggregates and caused decrease of both
DARPP-32 and NeuN neuronal markers at one month post-injection suggesting that polyQ pathology may be
dependent on protein context. Finally, the reversibility of the pathology was assessed. Huntingtin expression
was turn ‘on’ for 1 month and then shut ‘off’ for 2 months. Recovery of DARPP-32 immunoreactivity and
clearance of huntingtin aggregates were observed in animals treated with doxycycline. These results suggest
that a tetracycline-regulated system may be particularly attractive to model Huntington’s disease and induce
early and reversible striatal neuropathology in vivo.
INTRODUCTION
Huntington’s disease (HD) is the most frequent hereditable
neurodegenerative disease of a group of nine disorders caused
by an expansion of CAG trinucleotide repeats encoding
polyglutamine (polyGln) residues (1,2). These diseases have
in common autosomal dominant inheritance, ubiquitous
expression of the corresponding proteins, the fact that the
polyGln tract becomes pathogenic upon reaching a certain size,
the presence of nuclear inclusions and the selective degenera-
tion of subpopulations of neurons. Studies performed on
transgenic or knock-in mice models of HD have provided
important clues on the molecular basis of mutant huntingtin
neurotoxicity (3–11). Interestingly, these animal models
recapitulate some of the early neuropathological features of
HD while the more advanced pathological features are not
observed. The transgenic models are also limited by the
occurrence of side effects and premature death associated
with the widespread overexpression of huntingtin (htt)
(3,12,13). To overcome some of these limitations, we have
produced lentiviral vectors overexpressing various mutant
htt fragments both in rats and primates (14,15). In rat
striatum, the overexpression of the first 171 amino acids of
the htt protein with 82 CAG repeats was associated with
neuronal dysfunction and astrogliosis leading to robust and
selective degeneration of GABAergic neurons 12 weeks post-
lentiviral injection (15). The severity of the pathology was
directly correlated with htt expression level and htt fragment
size (15), confirming that these parameters constitute key
factors for polyQ diseases modeling (16). Huntingtin being the
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largest polyglutamine-containing protein, the targeted over-
expression of full-length huntingtin (350 kDa) in animals
represents an important challenge to closely mimic the human
pathology, analyze the folding and processing of the protein
and reproduce all stages of the disease in a time frame
compatible with rodent life span.
In the present study, we have developed tetracycline-regulated
lentiviral vectors expressing the first 853 amino acids of htt. We
have recently shown that in the ‘on’ state, the expression level
reached with dual tetracycline-regulated vectors is 4- to 5-fold
higher than the housekeeping and constitutive phosphoglycerate
kinase 1 (PGK) promoter (17). This tetracycline-regulated
system was used to assess whether an increased htt expression
was associated with exacerbated and earlier striatal pathology in
adult rats. The neuronal dysfunction was analyzed on DARPP-
32- and NeuN-stained sections. In addition, the formation of
aggregates as well as the processing and translocation of
mutated htt in the nucleus were used to follow the appearance of
the pathology. Finally, taking advantage of the tetracycline-
regulated system, we have assessed the reversibility of the
pathological process by shutting-off htt expression. Yamamoto
and coworkers (10) showed that the down-regulation of htt
Exon 1 (htt67 with 94 CAG) expression in symptomatic mice
can reverse motor deficits and inclusions formation. The present
study extended these observations to a larger htt fragment.
RESULTS
Tetracycline-regulated vectors based on multiply attenuated
lentiviral packaging system (18,19) were used to produce
recombinant viruses (Fig. 1A). The cDNA encoding for wild-
type (19 CAG) or mutated (82 CAG) htt fragments of 853
amino acids (htt853) was cloned in the SIN-W-TRE backbone
(17). The functionality of the vectors was assessed in 293T
cells infected with SIN-W-TRE-htt853-19Q (TRE-853-19Q) or
SIN-W-TRE-htt853-82Q (TRE-853-82Q) alone or in combina-
tion with the transactivator (PGK-tTA1; Fig. 1A and B) (17).
Huntingtin fragments corresponding to wild-type and mutated
proteins were detected in cells co-infected with the PGK-tTA1
(Fig. 1B, lanes 3 and 5). Importantly, the expression level was
6.8 2.1 times higher than endogenous htt, confirming that the
tetracycline system led to strong transgene expression (Fig. 1B).
The addition of doxycycline in the culture medium reduced htt
expression to background levels (Fig. 1B, lanes 4 and 6).
Owing to the intrinsic leakiness of the TRE promoter (20,21), a
weak signal was detected in cells infected with the TRE-853-
19Q or -82Q viruses alone (Fig. 1B, lanes 1 and 2).
A pilot study was performed in adult rats to verify the
hypothesis that tetracycline-regulated htt853-82Q overexpression
would lead to an exacerbated pathology compared to a lentiviral
vector with the phosphoglycerate kinase promoter (PGK-853-
82Q) (15). We have previously shown that a diffuse loss of
DARPP-32 staining appeared 3 months post-injection of PGK-
853-82Q and that a neuronal dysfunction, with a large DARPP-
32 depleted area, is obtained at 6 months (15). In this study, the
animals were sacrificed 1 month post-injection. Under these
conditions, DARPP-32 expression was unaltered in PGK-853-
82Q-injected rats, while a neuronal dysfunction was already
detected on striatal sections from TRE-853-82Q-injected rats
(Fig. 2). These results support the hypothesis that an increased htt
expression level accelerates the pathological process.
To further characterize the onset and progression of the
pathology, rats were simultaneously injected with PGK-tTA1
and TRE-853-19Q/TRE-853-82Q vectors in the left and right
striatum, respectively. The animals were maintained in the ‘on’
(dox) or ‘off’ (þdox) states for 1, 2 or 3 months. Wild-type
and mutated htt proteins were detected around the injection
site, in the ‘on’ groups (Fig. 3A), while htt expression was
below detection level in the ‘off’ groups (data not shown). The
residual expression of htt853-82Q in animals (‘off’ group) and
the overexpression of htt853-19Q (‘on’ group) did not lead to
any significant pathology based on DARPP-32 and NeuN
expression (Fig. 3B and data not shown). In TRE-853-82Q
injected animals (‘on’ group), a DARPP-32 down-regulation
(13.4 0.7% of the striatum) was already visible at 1 month
(Fig. 3B and C). This pathology is due to striatal dysfunction as
indicated by the absence of NeuN down-regulation (Fig. 4B).
The differential effect on the DARPP-32/NeuN neuronal
markers was still present at 3 months (data not shown) and
was also observed in animals injected with the PGK-853-82Q
vector (Fig. 4C and D). In contrast, both markers were affected
at 1 month in PGK-171-82Q injected rats (Fig. 4E and F). The
lesion size, however, suggest that DARPP-32 expression is
more sensitive to polyQ toxicity than NeuN (Fig. 4E and F).
Figure 3A shows that nuclear (NIs) and cytoplasmic (CIs)
inclusions were already present one month post-injection of
TRE-853-82Q. We have therefore examined whether a proteo-
lytic cleavage was occurring in these animals. Various htt
breakdown products have been identified in cellular or animal
models of HD and on brain tissue from affected patients (22–
25). In this study, we have used antibodies recognizing the N-
terminal part of htt (2B4 mAb) (26) or an epitope located
between amino acids 115–129 (1H6 mAb) to analyze the
Figure 1. (A) Lentiviral vector systems used for the expression of tetracycline-
regulated of wild-type (19 CAG) or mutated (82 CAG) huntingtin (htt)
proteins; (B) western blot of 293T cells infected with (1) SIN-TRE-853-19Q;
(2) SIN-TRE-853-82Q; (3) SIN-TRE-853-19Q þ SIN-PGK-tTA1/Dox; (4)
SIN-TRE-853-19Q þ SIN-PGK-tTA1/þDox; (5) SIN-TRE-853-82Q þ SIN-
PGK-tTA1/Dox; (6) SIN-TRE-853-82Q þ SIN-PGK-tTA1/þDox; (7) non-
infected 293T cells. The western blot analysis was performed three times.
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processing and subcellular localization of various htt fragments
(Fig. 5A) (26,27). In animals injected with the TRE-853-19Q
construct, a cytoplasmic immunoreactivity was observed with
both antibodies (Fig. 5B). In TRE-853-82Q injected animals,
nuclear and neuritic inclusions were densely stained with the
2B4 antibody, while a weak cytoplasmic staining was obtained
with the 1H6 antibody (Fig. 5B). In agreement with the data
previously described in HD patients and in vitro systems, this
suggest that the majority of NIs and CIs formed by TRE-853-
82Q expression are composed of N-terminal htt fragments
cleaved between 2B4 and 1H6 epitopes (26). To further analyze
the processing and translocation of htt in the nucleus,
immunohistochemical staining was performed on striatal
sections from PGK-171-82Q injected rats (15). In these animals,
NIs were stained with both antibodies, suggesting that, contrary
to the htt853 protein, this short htt fragment is not subjected to
protease cleavage before being transported into the nucleus
(Fig. 5C).
In the last part of this study, we have taken advantage of the
tetracycline system to investigate the reversibility of TRE-853-
82Q pathology. Huntingtin expression was turned ‘on’ for 1
month and then shut ‘off’ for an extra 2 months. Controlled
animals were either maintained in the ‘on’ state for 1 and 3
months or in the ‘off’ state for 3 months. This experimental
paradigm was chosen because TRE-853-82Q overexpression
for a month is associated with neuronal dysfunction with no
indication of cell death. In the animals switched ‘off’ for 2
months, a 61.4 4.3% recovery of DARPP-32 immunoreac-
tivity was observed (Fig. 6A and B). This recovery was
accompanied by a clearance of htt aggregates (Fig. 6C). Recent
studies have demonstrated that minocycline, a second-genera-
tion tetracycline antibiotic, delays the onset of symptoms and
prolongs the life span of R6/2 mice (28). To exclude the
possibility that the reversibility of the neuropathology was due
to a direct effect of doxycycline, rats were stereotaxically
injected with viruses constitutively expressing the htt171-82Q
(PGK-171-82Q) (15) and 548-128Q (PGK-548-128Q) frag-
ments and half the animals were treated with doxycycline for 1
month. Neither the cellular dysfunction (Fig. 7A and B) nor the
formation of aggregates was affected by the addition of
doxycycline (Fig. 7C). These data further confirm that reversal
of the pathology was due to htt shut ‘off’ and not to a direct
effect of doxycycline.
DISCUSSION
Rodent models of HD expressing full-length or large htt
fragments and reproducing the late stages of the disease have
not yet been described. In an attempt to overcome this limitation
and closely recapitulate the human pathology, very high
transgene expression or extremely long CAG tracts mimicking
juvenile form of HD have been proposed (2,11,29,30). We have
previously reported that lentiviral vectors represent a powerful
and flexible tool for targeted overexpression of disease-causing
genes in vivo and that the protein levels reached with this
system are higher than with transgenic techniques (15). The
sustained and local lentiviral-mediated delivery of a short htt
fragment of 171 amino acids and 82 CAG repeats was, for
example, associated with a severe striatal degeneration at
3 months (15). However, increasing the size of the htt fragments
(853 or 1520AA) to include caspases, calpains and/or proteases
cleavage sites implicated in HD pathogenesis significantly
delays the appearance of a pathology (27,31–35). Neuronal
dysfunction with no indication of cell death was obtained up to
6 months post-injection (15).
In the present study, we have used tetracycline-regulated
lentiviral vectors to further push transgene expression level and
induce an early pathological onset with a large htt fragment. We
have recently demonstrated the potency of this dual tetracycline
system to regulate CNTF expression in vivo (17). In the ‘on’
state, the transgene expression was 4- to 5-fold higher than the
housekeeping and constitutive phosphoglycerate kinase 1
(PGK) promoter (17). Lentiviral vectors coding for the first
853 amino acids of wild-type and mutated htt driven by the
tetracycline operator and minimal CMV promoter were
produced (TRE-853-19/82Q). The tetracycline repressor tetR
fused to four copies of the minimal transcriptional activation
domain of VP16 (36) was cloned in the SIN-W-PGK transfer
vector (37). In a side-by-side comparison with PGK-853-19/
82Q vectors, we confirmed that higher htt levels (TRE-853-
82Q) significantly accelerated the kinetics of appearance of
striatal dysfunction. A loss of DARPP-32 expression, NIs and
CIs was observed as early as 1 month after the injection of the
TRE-853-82Q vector compared with 6 months with the PGK-
853-82Q vector. Interestingly, NeuN expression was not
decreased under these conditions. This differential effect on
neuronal markers (DARPP-32/NeuN) was still present at 3
months whereas both markers were down-regulated at 1 month
in animals injected with the short htt171-82Q fragment. These
results strengthen the concept of context-dependent polyQ
toxicity (38–40) and suggest that the molecular mechanisms
leading to striatal dysfunction might differ with the various htt
peptides. Data on the processing of htt further illustrate this
notion. PolyQ aggregates formed by htt171-82Q or htt853-82Q
Figure 2. Side-by-side comparison of constitutive versus regulated htt853-82Q
expression. DARPP32 down-regulation in rats injected with PGK-853-82Q (A
and B) or TRE-853-82Q þ PGK-tTA1 (C and D) lentiviral vectors.
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proteins present differential immunoreactivity with the 1H6
antibody, indicating that NIs and CIs are built up with htt
polypeptides of different sizes. A recent report showed that NIs
in HD brains and in a cellular model are built up by a short N-
terminal htt fragment, named cp-A, which is released by
cleavage between the polyQ stretch and the epitope of 1H6
mAb (Fig. 5) (27). In agreement with this, our present result
indicates that htt853-82Q was also processed to release
fragments similar in size to cp-A that translocate and aggregate
in the nucleus. In contrast, in htt171-82Q-injected animals NIs
were 1H6 positives, suggesting that the htt171 form is short
enough to passively translocate to the nucleus without the need
of proteolysis. Whether the differential build-up of aggregates
in htt171-82Q- and htt853-82Q-injected rats has an impact on
the pathological process remains to be clarified. In vitro and in
vivo experiments indicate that htt is a substrate for caspases,
calpains and aspartyl proteases, suggesting that sequential
cleavage of htt may occur (27,28,32–34). To decipher the role
of proteolysis in htt toxicity, expression of large htt constructs
bearing mutations of the cleavage sites will be required.
Lentiviral-based vectors represent a rapid and efficient system
to deliver such constructs in the striatum of rat.
Figure 3. (A) 2B4 Ab staining revealing exogenous human huntingtin expression in the striatum of rats injected with PGK-tTA1 and TRE-853-19Q/82Q vectors.
High magnification showing the accumulation of cytoplasmic (CI) and nuclear inclusions (NI) in rats injected with the TRE-853-82Q vector as compared with the
diffuse staining in animals injected with the TRE-853-19Q vector; (B) DARPP-32 staining in the striatum of rats injected with TRE-853-82Q/tTA1 vectors and
maintained 3 months in either ‘on’ or ‘off’ states; (C) quantification of DARPP-32 down-regulation 1, 2 and 3 months post-injection of lentiviruses in animals
treated or not with doxycycline. Results are expressed as a ratio of DARPP-32 optical density (OD) between lesioned and non-lesioned areas. One-way
ANOVA, F(5,10)¼ 27.68, P< 0.001. Post-hoc comparison: ‘on’ versus ‘off’ for each time point, *P< 0.001. Post-hoc comparison: ‘on’ versus ‘on’ and ‘off’
versus ‘off’ was non-significant at all time points.
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The tetracycline operator is not only a powerful promoter
leading to extremely high transgene levels upon transactivator
expression but is also a system allowing suppression of mutant
htt synthesis by peripheral doxycycline administration.
Conditional mice models of HD expressing the first exon of
mutant htt have already provided important information on the
reversibility of the pathology and have demonstrated that the
progression of the disease relies on a constant expression of htt
and that behavioral deficits and neuronal dysfunctions can be
blocked and aggregates cleared (10). Determining whether
reversible damage is produced with longer htt fragments is
important not only for the development of effective therapies
but also to determine the time-window of intervention. In TRE-
853-82Q animals, doxycycline administration for 2 months
abolishes transgene expression and significantly decreases
striatal dysfunction and inclusion formation. These effects
cannot be attributed to a neuroprotective effect of doxycycline
based on data obtained in rat injected with the PGK-171-82Q
and PGK-548-128Q vectors and treated with doxycycline for a
month. Altogether, these data suggest that a decrease in the
cellular load of abnormal polyQ may be sufficient to restore
neuronal phenotype and to induce proteasome degradation of
cytoplasmic and nuclear inclusions. Strategies aiming at
decreasing the disease-related transcript with RNA interference
may, therefore, be of therapeutic relevance (41–43). The
versatility and efficiency of lentiviral gene transfer in the
CNS of adult animals associated with the availability of
conditional models of HD provide a unique opportunity to
address some of these questions and move further toward a cure
for HD.
Figure 4. Differential susceptibility of DARPP-32 (A, C, E) and NeuN (B, D, F) markers, 1 month post-injection of the constitutive PGK-171-82Q vector (A and B),
6 months post-injection of the constitutive PGK-853-82Q vector (C and D) and one month post-injection of tetracycline-regulated TRE-853-82Q system (E and F).
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MATERIALS AND METHODS
Lentiviral vector production
The cDNA coding for the first 853 amino acids of wild-type or
mutated htt (htt853-19Q or htt853-82Q) was cloned in a SIN-
W transfer vector containing the Tet-response element (TRE;
BD Bioscience Clontech, Palo Alto, CA, USA) with seven
direct repeats of the TetO operator sequence, upstream of a
minimal CMV promoter. The cDNA coding for the first 548
amino acids of mutated (128 CAG) htt was kindly provided by
Dr M.R. Hayden (44) and cloned in the SIN-W-PGK transfer
vector (37). Lentiviral vectors encoding for the first 171 amino
acids of mutated (82 CAG) htt (15) and for the tetracycline-
controlled transactivator tTA1 (17) [tetracycline repressor tetR
fused to four copies (4F) of the minimal transcriptional
activation domain of VP16 (36)] were also used in this study.
The lentiviral particles were produced and resuspended in
phosphate-buffered saline (PBS)/1% bovine serum albumin as
previously reported (45,46). The particle content of viral
batches was determined by p24 antigen ELISA (PerkinElmer
Life Sciences, Boston, USA).
Western blot analysis
293T cells were infected with the lentiviral vectors matched for
particle content (200 ng of p24 antigen per well per vector) and
cultured with or without addition of doxycycline (1 mg/ml) to
the medium. Cellular lysates were harvested 4 days after
infection in lysis buffer (125 mM Tris–HCl/0.5% SDS/1%
Nonidet P-40) containing protease inhibitors (Roche Pharma,
Basel, Switzerland). Protein concentrations of cytoplasmic
fractions were determined by the BCA protein assay kit (Pierce
Biotechnology Inc., Rockford, IL, USA). Equal amounts of
protein (50 mg) were loaded on 7.5% sodium dodecyl sulfate
(SDS) polyacrylamide gel and transferred onto nitrocellulose
membrane (Schleicher and Schuell Bioscience GmbH, Dassel/
Relliehausen, Germany). Immunoblotting was performed using
a mouse monoclonal antibody (MAb2166; 1 : 10 000;
Chemicon International Inc., Temecula, USA) directed against
the 181–810 amino acid sequence of human htt followed by
goat anti-mouse horseradish peroxydase (HRP) antibody
(1 : 2000; DakoCytomation AG, Zug, Switzerland).
Visualization of the proteins was achieved using ECL and
chemiluminescence detection kit (Amersham Biosciences
Europe GmbH, Freiburg, Germany) in a Multimage Light
Cabinet (Alpha Innotech Corporation, San Leandro, USA).
In vivo experiments
Adult female Wistar rats (Iffa Credo/Charles River, Les Oncins,
France), weighing 180–200 g were used. The animals were
housed in a temperature-controlled room and maintained on a
12 h light/dark cycle. Food and water were available ad libitum.
For tetracycline-regulated expression studies, rats were main-
tained in the ‘off’ state with the addition of 200 mg/l
doxycycline (Dox, Sigma Chemical Co., Saint Louis, MO,
USA) in drinking water containing 40 g/l sucrose (correspond-
ing approximately to 20 mg Dox/rat/day), while the ‘on’ group
received only sucrose. The experiments were carried out in
accordance with the European Community Council directive
(86/609/EEC) for the care and use of laboratory animals.
Injection of lentiviruses
Concentrated viral stocks were thawed and resuspended by
repeated pipetting. Htt171-82Q-, htt548-128Q-, htt853-19Q-,
htt853-82Q- and tTA1-expressing lentiviral vectors were
stereotaxically injected into the striatum of ketamine (75 mg/
kg, i.p.) and xylazine (10 mg/kg, i.p.) anesthetized animals
using an Hamilton syringe with a 34-gage blunt-tip needle
(Hamilton, Reno, NV, USA). A 1 : 4 ratio in particle contents
was used for lentiviral co-injection with 200 000 ng of p24/ml
of PGK-tTA1 and 50 000 ng of 24/ml of TRE-853-19Q/82Q.
Particle content was matched to 20 000 ng of p24/ml for single
lentiviral injections. The viral suspensions (4 ml) were injected
at 0.2 ml/min by means of an automatic injector (Stoelting Co.,
Wood Dale, USA) and the needle was left in place for an
additional 5 min. The stereotaxic coordinates were: 0.5 mm
rostral to bregma; 3 mm lateral to midline; and 5 mm from the
skull surface. The skin was closed using a 6–0 Prolene1 suture
(Ethicon, Johnson and Johnson, Brussels, Belgium).
Figure 5. (A) Schematic representation of huntingtin protein with two putative
protease cleavage sites (CpA and CpB) and 2B4 and 1H6 epitopes; (B) 2B4 and
1H6 stained sections from rats injected with PGK-tTA1 and TRE-853-19Q/82Q
vectors and sacrificed at 1 month; (C) 2B4 and 1H6 stained striatal sections
from rats injected with PGK-171-82Q vector and sacrificed at 1 month. NI:
nuclear inclusions. CI: cytoplasmic inclusions.
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Histological processing
One, 2 or 3 months after lentiviral injection, the animals were
given a sodium pentobarbital overdose and transcardially
perfused with saline and 4% paraformaldehyde, 10% picric
acid. The brains were removed and postfixed in 4% parafor-
maldehyde, 10% picric acid for 24 h and finally cryoprotected
in 25% sucrose/0.1 M phosphate buffer for 48 h. The brains were
frozen in dry ice and 25 mm coronal sections were cut on a
sliding microtome cryostat (Cryocut 1800, Leica Microsystems
AG, Glattbrugg, Switzerland) at 20C. Slices throughout the
entire striatum were collected and stored in 48-well trays
(Costar, Cambridge, MA, USA) as free-floating sections in PBS
supplemented with 0.12 mM sodium azide. The trays were stored
at 4C until immunohistochemical processing. Striatal sections
from injected rats were processed by immunochemistry for
dopamine and cAMP-regulated phosphoprotein of a molecular
mass of 32 kDa (DARPP-32, 1 : 8000; Chemicon International
Figure 6. (A) Effect of htt853-82Q shut-off on DARPP-32 expression; (B) quantification of DARPP-32 down-regulation in rats injected with TRE-853-19Q/
82QDox at 1, 2 and 3 months. One-way ANOVA, F(3,10)¼ 22.08, P< 0.001. Post-hoc comparison: 1 month ‘on’ versus 1 month ‘on’ and 2 months ‘off’,
¥P< 0.01; 3 months ‘on’ versus 1 month ‘on’ and 2 months ‘off’, *P< 0.01; 1 month ‘on’ and 2 months ‘off’ versus 3 months ‘off’, #P< 0.05; 1 month
‘on’ versus 3 months ‘on’, non-significant. (C) Htt stained brain sections (2B4) from rats injected with TRE-853-82Q showing the absence of htt expression
in animals maintained 3 months ‘off’, the accumulation of aggregates in 1 and 3 months ‘on’ rats and finally the clearance of neuritic and neuronal inclusions
in animals expressing htt for 1 month and switched ‘off’ for 2 months.
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Inc., Temecula, USA), Neuronal nuclei (NeuN, 1 : 400;
Chemicon, CA, USA) htt (2B4, 1/200; 1H6, 1/100) as
previously described (46). The sections were mounted, dehy-
drated by passing twice through ethanol and toluol and cover-
slipped with Merckoglas1 (EM Science, Gibbstown, USA).
Image analysis
The htt lesions were analyzed by digitizing from 14 DARPP-
32-stained sections per animal (200 mm between sections) with
a slide scanner and by quantifying the optical density with an
image analysis program (NIH-image, Version 1.6.2, National
Institute of Health, USA). Sections throughout the entire
striatum were analyzed. Data are expressed as the ratio of
evaluated DARPP-32 optical density. The optical density
represents the average grey value of all pixels measured on
the lesioned area divided by the total number of pixels of a non-
lesioned area. The corpus callosum and the anterior commis-
sure were used to delineate the striatal area.
Data analysis
Immunostaining quantifications are expressed as mean SEM.
Statistical analysis was performed by one-way analysis of
variance (ANOVA) followed by a Newman–Keuls post-hoc test
(Statistica 5.1, Statsoft Inc., USA). The significance level was
set at P< 0.05.
Figure 7. (A) Doxycycline treatment in rats injected with the constitutive PGK-171-82Q and PGK-548-128Q vectors has no effect on DARPP-32 down-regulation;
(B) quantification of DARPP-32 staining at one month. The difference between Dox and saline injected groups was not significant on the measure of DARPP-32
down-regulation [group down-regulation, F(3,8)¼ 0.2, P¼ 0.89]. (C) the addition of doxycycline in the drinking water of rats injected with PGK-171-82Q
vector has no effect on the formation of Htt inclusions.
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